[go: up one dir, main page]

AR078408A1 - DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC - Google Patents

DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC

Info

Publication number
AR078408A1
AR078408A1 ARP100103446A ARP100103446A AR078408A1 AR 078408 A1 AR078408 A1 AR 078408A1 AR P100103446 A ARP100103446 A AR P100103446A AR P100103446 A ARP100103446 A AR P100103446A AR 078408 A1 AR078408 A1 AR 078408A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
optionally substituted
phenyl
carbonyl
Prior art date
Application number
ARP100103446A
Other languages
Spanish (es)
Inventor
Muzaffar Alam
Wylie Solang Palmer
Tania Silva
Robert Stephen Wilhelm
Ronald Charles Hawley
Joshua Kennedy-Smith
Ana Elena Minatti
Bois Daisy Joe Du
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR078408A1 publication Critical patent/AR078408A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se describen también métodos de obtencion de los compuestos y el uso de los compuestos para el tratamiento de enfermedades asociadas con los canales de calcio activados con la liberacion de calcio (CRAC). Reivindicacion 1: Un compuesto de la formula (1): en la que: R1 es: - fenilo sustituido una, dos o tres veces por un grupo o grupo elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; halogeno; halo-alquilo C1-6; halo-alcoxi C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; aminocarbonilo; aminosulfonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; amino; hidroxi; sulfonilmorfolina; sulfonilmetilpiperazina; heterociclilo; fenilo que puede estar opcionalmente sustituido; o heteroarilo que puede estar opcionalmente sustituido; - piridinilo opcionalmente sustituido una o dos veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; halogeno; halo-alquilo C1-6 nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; amino; oxo; hidroxi; heterociclilo; fenilo que puede estar opcionalmente sustituido; o heteroarilo que puede estar opcionalmente sustituido; - pirimidinilo opcionalmente sustituido una o dos veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; halogeno; halo-alquilo C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; amino; oxo; hidroxi; heterociclilo; fenilo que puede estar opcionalmente sustituido; o heteroarilo que puede estar opcionalmente sustituido; o - un anillo heteroarilo de cinco eslabones opcionalmente sustituido una, dos o tres veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; cicloalquilo C3-6; alcoxi C1-6; halogeno; halo-alquilo C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; amino; oxo; hidroxi; heterociclilo; fenilo que puede estar opcionalmente sustituido; y heteroarilo que puede estar opcionalmente sustituido; o dos de dichos sustituyentes junto con los átomos a los que están unidos pueden formar un fenilo fusionado con el anillo heteroarilo de cinco eslabones; es: - cicloalquilo C3-6; - fenilo sustituido una, dos o tres veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; alcoxihidroxi C1-6; halogeno; halo-alquilo C1-6; haloalcoxi C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; (alquil C1-6)-carbonilhidroxi; (alcoxi C1-6)-ciano; amino; hidroxi; fenilo que puede estar opcionalmente sustituido; o heteroarilo que puede estar opcionalmente sustituido; - piridinilo opcionalmente sustituido una o dos veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; halogeno; halo-alquilo C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonil- amino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; amino; oxo; hidroxi; fenilo que puede estar opcionalmente sustituido; o heteroarilo que puede estar opcionalmente sustituido; - pirimidinilo opcionalmente sustituido una o dos veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; halogeno; halo-alquilo C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; fenilo que puede estar opcionalmente sustituido; o heteroarilo que puede estar opcionalmente sustituido; o - un anillo heteroarilo de cinco eslabones opcionalmente sustituido una o dos veces por un grupo o grupos elegidos con independencia entre: alquilo C1-6; alcoxi C1-6; halogeno; halo-alquilo C1-6; cicloalquilo C3-6; halo-alcoxi C1-6; nitrilo; acetilo; (alcoxi C1-6)-carbonilo; (alquil C1-6)-carbonilamino; (alquil C1-6)-sulfanilo; (alquil C1-6)-sulfonilo; (alcoxi C1-6)-alquilo C1-6; hidroxi-alquilo C1-6; amino; oxo; hidroxi; fenilo que puede estar opcionalmente sustituido; y heteroarilo que puede estar opcionalmente sustituido; o dos de dichos sustituyentes junto con los átomos a los que están unidos pueden formar un fenilo fusionado con dicho anillo heteroarilo de cinco eslabones; R3 es hidrogeno; R3' es hidrogeno o alquilo C1-6; es un numero de 0 a 3; cada R4 se elige con independencia entre: hidrogeno; alquilo C1-6; alcoxi C1-6; halogeno; y halo-alquilo C1-6, y dicha línea discontinua es un enlace o está ausente, o una sal farmacéuticamente aceptable de los mismos.Methods of obtaining the compounds and the use of the compounds for the treatment of diseases associated with calcium channels activated with calcium release (CRAC) are also described. Claim 1: A compound of the formula (1): wherein: R1 is: - phenyl substituted once, twice or three times by a group or group independently selected from: C1-6 alkyl; C1-6 alkoxy; halogen; halo C1-6 alkyl; C1-6 haloalkoxy; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; aminocarbonyl; aminosulfonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; Not me; hydroxy; sulfonylmorpholine; sulfonylmethylpiperazine; heterocyclyl; phenyl that may be optionally substituted; or heteroaryl which may be optionally substituted; - pyridinyl optionally substituted once or twice by a group or groups chosen independently from: C1-6 alkyl; C1-6 alkoxy; halogen; halo-C1-6 alkyl nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; Not me; oxo; hydroxy; heterocyclyl; phenyl that may be optionally substituted; or heteroaryl which may be optionally substituted; - pyrimidinyl optionally substituted once or twice by a group or groups chosen independently from: C1-6 alkyl; C1-6 alkoxy; halogen; halo C1-6 alkyl; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; Not me; oxo; hydroxy; heterocyclyl; phenyl that may be optionally substituted; or heteroaryl which may be optionally substituted; or - a five-link heteroaryl ring optionally substituted once, twice or three times by a group or groups chosen independently from: C1-6 alkyl; C3-6 cycloalkyl; C1-6 alkoxy; halogen; halo C1-6 alkyl; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; Not me; oxo; hydroxy; heterocyclyl; phenyl that may be optionally substituted; and heteroaryl which may be optionally substituted; or two of said substituents together with the atoms to which they are attached may form a phenyl fused with the five-link heteroaryl ring; is: - C3-6 cycloalkyl; - phenyl substituted once, twice or three times by a group or groups chosen independently from: C1-6 alkyl; C1-6 alkoxy; C1-6 alkoxyhydroxy; halogen; halo C1-6 alkyl; C1-6 haloalkoxy; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; (C1-6 alkyl) -carbonylhydroxy; (C1-6 alkoxy) -cyano; Not me; hydroxy; phenyl that may be optionally substituted; or heteroaryl which may be optionally substituted; - pyridinyl optionally substituted once or twice by a group or groups chosen independently from: C1-6 alkyl; C1-6 alkoxy; halogen; halo C1-6 alkyl; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonyl-amino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; Not me; oxo; hydroxy; phenyl that may be optionally substituted; or heteroaryl which may be optionally substituted; - pyrimidinyl optionally substituted once or twice by a group or groups chosen independently from: C1-6 alkyl; C1-6 alkoxy; halogen; halo C1-6 alkyl; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; phenyl that may be optionally substituted; or heteroaryl which may be optionally substituted; or - a five-link heteroaryl ring optionally substituted once or twice by a group or groups independently selected from: C1-6 alkyl; C1-6 alkoxy; halogen; halo C1-6 alkyl; C3-6 cycloalkyl; C1-6 haloalkoxy; nitrile; acetyl; (C1-6 alkoxy) -carbonyl; (C1-6 alkyl) -carbonylamino; (C1-6 alkyl) -sulfanyl; (C1-6 alkyl) -sulfonyl; (C1-6 alkoxy) -C 1-6 alkyl; hydroxyC 1-6 alkyl; Not me; oxo; hydroxy; phenyl that may be optionally substituted; and heteroaryl which may be optionally substituted; or two of said substituents together with the atoms to which they are attached may form a phenyl fused with said five-link heteroaryl ring; R3 is hydrogen; R3 'is hydrogen or C1-6 alkyl; it is a number from 0 to 3; each R4 is independently selected from: hydrogen; C1-6 alkyl; C1-6 alkoxy; halogen; and haloC 1-6 alkyl, and said broken line is a bond or is absent, or a pharmaceutically acceptable salt thereof.

ARP100103446A 2009-09-24 2010-09-22 DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC AR078408A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24552109P 2009-09-24 2009-09-24
US37806210P 2010-08-30 2010-08-30

Publications (1)

Publication Number Publication Date
AR078408A1 true AR078408A1 (en) 2011-11-02

Family

ID=43432437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103446A AR078408A1 (en) 2009-09-24 2010-09-22 DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC

Country Status (12)

Country Link
US (1) US20110071150A1 (en)
EP (1) EP2480529A1 (en)
JP (2) JP2013505913A (en)
KR (1) KR20120068947A (en)
CN (1) CN102574788A (en)
AR (1) AR078408A1 (en)
BR (1) BR112012006630A2 (en)
CA (1) CA2771026A1 (en)
MX (1) MX2012003539A (en)
RU (1) RU2012116207A (en)
TW (1) TW201121952A (en)
WO (1) WO2011036130A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423962B (en) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
JP2013530180A (en) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ Aryl substituted indoles and uses thereof
US20130109720A1 (en) * 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
WO2013092444A1 (en) * 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag Diazaindole inhibitors of crac
US20130158049A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US20130158066A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
MX2015004500A (en) * 2012-10-17 2015-07-06 Hoffmann La Roche 6-aminoindole derivatives as trp channel antagonists.
JP5758864B2 (en) 2012-11-08 2015-08-05 ファナック株式会社 Brake drive control device for quickly changing the brake state from the released state to the engaged state
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
EP2970119B1 (en) * 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
EP3033342A1 (en) * 2013-08-13 2016-06-22 Grünenthal GmbH Annelated pyrroles and their use as crac inhibitors
US9802920B2 (en) 2013-12-13 2017-10-31 Hoffman-La Roche Inc. Inhibitors of bruton's tyrosine kinase
KR101824346B1 (en) 2013-12-13 2018-01-31 에프. 호프만-라 로슈 아게 Inhibitors of bruton's tyrosine kinase
CN106957252B (en) * 2014-11-19 2019-11-19 连云港恒运药业有限公司 A kind of proton pump inhibitor intermediate and preparation method thereof
MX378998B (en) 2015-06-03 2025-03-11 Bristol Myers Squibb Co 4-HYDROXY-3-(HETEROARYL)PYRIDIN-2-ONE APELIN RECEPTOR AGONISTS (APJ) FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS.
TW201835036A (en) 2017-02-27 2018-10-01 瑞士商隆薩有限公司 Method for preparation of 1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-ol
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUNDS AS AhR MODULATORS
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
JP7287964B2 (en) 2017-12-15 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー substituted indole ether compounds
SG11202005696YA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
SG11202005700SA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
MX2020006014A (en) 2017-12-20 2020-08-17 Bristol Myers Squibb Co Diazaindole compounds.
ES2965182T3 (en) * 2017-12-20 2024-04-11 Bristol Myers Squibb Co Aryl and heteroaryl substituted indole compounds
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
BR112021004893A2 (en) 2018-09-14 2021-06-01 Rhizen Pharmaceuticals A G compositions comprising a crac inhibitor and a corticosteroid and methods of using them
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
CN112955450A (en) 2018-10-24 2021-06-11 百时美施贵宝公司 Substituted indole and indazole compounds
KR102911861B1 (en) 2018-10-24 2026-01-12 브리스톨-마이어스 스큅 컴퍼니 substituted indole dimer compounds
ES2987832T3 (en) 2019-05-09 2024-11-18 Bristol Myers Squibb Co Substituted benzimidazolone compounds
US12448395B2 (en) 2019-10-01 2025-10-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
WO2021067657A1 (en) 2019-10-04 2021-04-08 Bristol-Myers Squibb Company Substituted carbazole compounds
TW202227432A (en) 2020-08-19 2022-07-16 美商必治妥美雅史谷比公司 Substituted bicyclic compounds useful as inhibitors of tlr9
CN115043770B (en) * 2022-07-21 2023-09-08 南京大学 Light-induced synthesis method of indole/azaindole compounds
CN115124410B (en) * 2022-08-13 2024-06-04 上海珂华生物科技有限公司 Preparation method of 2-fluoro-4-hydroxybenzaldehyde

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5785055A (en) * 1980-11-18 1982-05-27 Konishiroku Photo Ind Co Ltd Silver halide photographic recording material
JP2894617B2 (en) * 1989-12-16 1999-05-24 帝国臓器製薬株式会社 2-phenylindole derivatives
FR2824827B1 (en) * 2001-05-17 2004-02-13 Fournier Lab Sa NOVEL 5-PHENYL-1H-INDOLE ANTAGONIST DERIVATIVES OF INTERLEUKIN-8 RECEPTORS
WO2003099206A2 (en) * 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
KR101472248B1 (en) * 2006-02-10 2014-12-16 서미트 코포레이션 피엘씨 Treatment of duchenne muscular dystrophy
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
WO2010045188A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
NZ595410A (en) * 2009-03-27 2013-12-20 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
KR20120068947A (en) 2012-06-27
JP2013505913A (en) 2013-02-21
CA2771026A1 (en) 2011-03-31
RU2012116207A (en) 2013-10-27
MX2012003539A (en) 2012-04-30
TW201121952A (en) 2011-07-01
WO2011036130A1 (en) 2011-03-31
JP2012246302A (en) 2012-12-13
US20110071150A1 (en) 2011-03-24
CN102574788A (en) 2012-07-11
BR112012006630A2 (en) 2016-05-03
EP2480529A1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
AR078408A1 (en) DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC
AR127309A2 (en) PYRDAZINONE DERIVATIVES
AR119651A1 (en) HETEROCYCLIC AND HETEROARYL COMPOUNDS TO TREAT HUNTINGTON'S DISEASE
AR084425A1 (en) HETEROCICLIC DERIVATIVES OF 8-AZABICICLO [3.2.1] OCTAN-8-ILO, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS TO PREPARE THEM AND INTERMEDIARIES AND USE OF THE SAME TO TREAT HEPATIC PATHOLOGIES SUCH AS DYSPIPHERMES AND HYPERTHOLESTERS
AR072952A1 (en) 2-IMINO-3-METHYL-PIRROLOPIRIMIDINONA PHENYL-REPLACED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE
AR077328A1 (en) DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
CL2011003302A1 (en) Compounds derived from alkyl sulfonic acid amide; pharmaceutical composition; use of the compounds as modulators of glutamate dysfunction to prevent or treat neurological and psychiatric disorders such as schizophrenia, Alzheimer's disease, attention deficit / hyperactivity disorders, hearing loss, among others.
AR065280A1 (en) ANTIPARASITARY AGENTS
AR068115A1 (en) DERIVED FROM PIRAZOLCARBOXILICO ACID PRODUCTION METHOD OF THE SAME AND FUNGICIDE
DK1833799T3 (en) 3-Phenyl-pyrazole derivatives as modulators of 5-HT-2α-serotonin receptor useful for the treatment of diseases related thereto
MX388468B (en) MULTICYCLIC COMPOUNDS AND METHODS OF USING THEM.
AR076550A1 (en) INHIBITORS OF THE JANUS TIROSINA KINASA (JAK)
EA201001680A1 (en) COMPOUNDS OF BENZOLSULPHONAMIDTIAOSOL AND OXAZOL
CL2011000986A1 (en) Halosubstituted compounds; use of said compounds to combat animal pests; procedure for the preparation of phytoprotectors; procedure to fight pests; and intermediary compounds.
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
AR081058A1 (en) DERIVATIVES OF ARILMETOXI ISOINDOLINA, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF CANCER.
DOP2007000018A (en) INDOL SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS
DK2080516T3 (en) Use of isothiocyanate derivatives as anti-myeloma agents
NO20081034L (en) Pyrimidine Compounds as Serotonin Receptor Modulators
EA201171488A1 (en) LXR MODULATORS
AR078722A1 (en) DERIVATIVES OF 2-OXO-1-PIRROLIDINILA IMIDAZOTIADIAZOL
CR20120524A (en) COMBINATIONS CONTAINING 2,3-DIHYDROIMIDAZO [1,2-C] REPLACED QUINAZOLINE
EA201190293A1 (en) TRIPOLIDA SPIRITS
UY31554A1 (en) NEW INHIBITORS OF ACETIL COENZIMA TO CARBOXYLASE AND USES IN OBESITY TREATMENTS AND MELLITUS DIABETES
AR067648A1 (en) DERIVATIVES OF 2-AZA-BICYCLE [2,2,2] OCTOBER, USE OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure